Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos


Combining an anti-CD20 antibody with chemotherapy improved outcomes in patients with CLL and coexisting conditions. In this patient population, obinutuzumab was superior to rituximab when each was combined with chlorambucil. (Funded by F. Hoffmann-La Roche; ClinicalTrials.gov number, NCT01010061.).

  • 123456 Profile photo of Madelyn

    In the CLL11 study, published 2014 in NEJM chlorambucil-obinituzumab showed significant PFS benefit over chlorambucil- rituximab in patients with CLL. The median PFS was 26.7 vs 15.2. In the initial publication there was no OS benefit of obi vs Rituxan, however in the final OS analysis in 2018 a OS benefit was seen with a HR of 0.76.